Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease

The Journal of Clinical Investigation
F H DurieR J Noelle

Abstract

Chronic and acute graft-versus-host disease (cGVHD and aGVHD) result from donor cells responding to host disparate MHC alleles. In cGVHD (H-2d-->H-2bd), heightened polyclonal immunoglobulin production is due to the interaction of donor allospecific helper T cells (Th) and the host B cells. In vivo administration of antibody to the ligand for CD40, gp39, blocked cGVHD-induced serum anti-DNA autoantibodies, IgE production, spontaneous immunoglobulin production in vitro, and associated splenomegaly. Antibody production remained inhibited for extended periods of time after termination of anti-gp39 administration. Antiallogeneic CTL responses induced in a GVHD were also prevented by the in vivo administration of anti-gp39 as was the associated splenomegaly. These data suggest that CD40-gp39 interactions are critical in GVHD and that CD40-gp39 may be a valuable ligand-receptor pair for targeting immunotherapeutic agents to control GVHD.

References

Nov 1, 1979·The Journal of Experimental Medicine·H von Boehmer, W Haas
May 7, 1992·Nature·R J ArmitageC R Maliszewski
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R J NoelleA Aruffo
Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Mar 1, 1991·The Journal of Experimental Medicine·L KoulovaB Dupont
Feb 1, 1990·The Journal of Experimental Medicine·S C MorrisR A Eisenberg
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C B ThompsonC H June
Mar 1, 1982·The Journal of Experimental Medicine·J A Keene, J Forman
Apr 1, 1993·The Journal of Experimental Medicine·E A Ranheim, T J Kipps
Sep 1, 1993·European Journal of Immunology·R J ArmitageM R Alderson
Feb 11, 1993·Nature·J P DiSantoG de Saint Basile
Mar 1, 1994·The Journal of Experimental Medicine·R S LeeH Auchincloss
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
Jan 1, 1993·The Journal of Experimental Medicine·E A ReapR A Eisenberg

❮ Previous
Next ❯

Citations

Mar 1, 1997·Arthritis and Rheumatism·L W MorelandW J Koopman
Jun 10, 1998·Springer Seminars in Immunopathology·N RameshR S Geha
Mar 1, 1996·Journal of Clinical Immunology·J E Buhlmann, R J Noelle
Dec 15, 1995·Journal of Immunological Methods·D HollenbaughA Aruffo
Sep 1, 1994·Immunology Today·F H DurieR J Noelle
Dec 10, 2003·Experimental Hematology·Warren D Shlomchik
Mar 27, 2001·Transplantation Proceedings·Y OhashiM Yamaguchi
Jan 1, 2003·Journal of Neuroimmunology·Kakuri M Omari, Katerina Dorovini-Zis
Nov 22, 1997·Current Opinion in Immunology·C P Larsen, T C Pearson
Jun 1, 1997·Current Opinion in Immunology·C van Kooten, J Banchereau
Oct 31, 1998·Current Opinion in Immunology·D M BriscoeA H Lichtman
Jun 6, 2003·Cytokine & Growth Factor Reviews·Steve W Granger, Sandra Rickert
Oct 29, 1998·British Journal of Haematology·K ClodiA Younes
Jan 19, 2002·Seminars in Hematology·Takanori Teshima, James L M Ferrara
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KarmannJ S Pober
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·N S KenyonC Ricordi
Jun 1, 1997·Immunological Reviews·B R BlazarD A Vallera
Jan 1, 1996·Annual Review of Immunology·T M FoyR J Noelle
Apr 1, 1996·The Journal of Clinical Investigation·Y OhkawaraM Jordana
Aug 1, 1996·The Journal of Clinical Investigation·M KoshyM K Crow
Feb 1, 1997·The Journal of Clinical Investigation·S FunakoshiW J Murphy
May 12, 2011·Disease Models & Mechanisms·Mark A Schroeder, John F DiPersio
Sep 7, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A BartlettS Munn
Apr 3, 2014·The Journal of Clinical Investigation·Kristi J WarrenBryna E Burrell
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·W W HancockL A Turka
Sep 26, 2008·Clinical & Developmental Immunology·David M MillerAldo A Rossini
Mar 30, 2007·Journal of Autoimmunity·Miri Blank, Yehuda Shoenfeld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.